Antagonizing NRG1-ERBB4 signaling pathway with spironolactone for the treatment of schizophrenia: results of a randomized controlled drug repositioning clinical trial - PubMed
3 hours ago
- #drug repositioning
- #clinical trial
- #schizophrenia
- A randomized controlled trial tested spironolactone's effect on schizophrenia by targeting the NRG1-ERBB4 signaling pathway, linked to cognitive impairment.
- 90 patients with schizophrenia were assigned to 100 mg or 200 mg spironolactone or placebo for three weeks, with working memory change as the primary endpoint.
- Prespecified analyses did not show significant superiority over placebo, but post-hoc sensitivity analyses suggested a potential positive effect on working memory.
- Spironolactone was well-tolerated, and longer or higher-dose trials are justified to further explore its efficacy in treating cognitive deficits in schizophrenia.